In our SYSUSH cohort (n = 170), immunohistochemical validation confirmed significantly fewer infiltrating CD8 + T cells in advanced CRC tumor centers (p = 0.008) and invasive margins (p = 0.004) compared to early-stage tumors (Fig. 2D). The gene discussed is CD8A; the disease is neoplasm.